Q-omics provides the consensus-scored MARCKSL1P1 profile across patient tissues and cancer cell-line models. MARCKSL1P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MARCKSL1P1 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, MARCKSL1P1 RNA expression shows 16,674 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, LUAD, and THYM as cancer lineages where MARCKSL1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARCKSL1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARCKSL1P1 survival associations across molecular data types. MARCKSL1P1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARCKSL1P1 RNA expression–survival associations across cancer types. High MARCKSL1P1 expression shows unfavorable associations in CESC, LUSC, MESO and SKCM, but favorable associations in ACC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify ACC as the clearest survival context for MARCKSL1P1 RNA expression.
This table summarizes MARCKSL1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MARCKSL1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARCKSL1P1 shows higher tumor expression in LUAD, STAD, HNSC, UCEC, CHOL and KIRP. The LUAD box plot shows higher MARCKSL1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.505, t-test p = .007).
This table shows molecular features associated with MARCKSL1P1 in patient tissues and cancer cell lines. In patient samples, MARCKSL1P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
